Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030919 | 0.92 | CFTR (0.81) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189058 | 0.92 | CFTR (0.83) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL16351175 | 0.91 | CFTR (0.80) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2036712 | 0.91 | CFTR (0.82) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| Lumacaftor SCHEMBL29355738 | 0.90 | CFTR (1.00) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| Lumacaftor SCHEMBL29355737 | 0.90 | CFTR (1.00) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| Lumacaftor SCHEMBL29370751 | 0.90 | CFTR (1.00) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL10066083 | 0.90 | CFTR (0.87) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189119 | 0.90 | CFTR (0.79) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| Lumacaftor SCHEMBL377028 | 0.90 | CFTR (1.00) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2018127846-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | LAURUS LABS LIMITED (IN) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018037350-A1 | SOLID FORMS OF LUMACAFTOR, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | LAURUS LABS LIMITED (IN) | 2018-03-01 | — | — | WO | disclosed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9776968-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170158676-A9 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2639223-B1 | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids | VERTEX PHARMA (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017017696-A1 | PROCESS FOR THE PREPARATION OF LUMACAFTOR | MYLAN LABORATORIES LIMITED (IN) | 2017-02-02 | — | — | WO | disclosed |
| US-20140330023-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-11-06 | — | — | US | disclosed |
| US-8816093-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20130274477-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-17 | — | — | US | disclosed |
| US-8461342-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120203006-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120190856-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124781-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | CFTR 182/4885NR1I2 2034/4885ADORA3 2478/4885 |
| US-20130274477-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20120203006-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20140330023-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | CFTR 1/4885NR1I2 88/4885ADORA3 1786/4885 |
| US-20170158676-A9 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20120190856-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.